Rapport Therapeutics, INC Form 4 insider transactions

NASDAQ
Third Rock Ventures V, L.P. and Third Rock Ventures VI, L.P. reported transactions involving the sale of Rapport Therapeutics, Inc. common stock.
NASDAQ
Third Rock Ventures V, L.P. sold 426,005 shares of Rapport Therapeutics, Inc. (RAPP) at a weighted average price of $40.317.
NASDAQ
Chief Development Officer Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics common stock.
NASDAQ
Rapport Therapeutics Chief Development Officer, Yeleswaram Krishnaswamy, reported the sale of company stock totaling over 20,000 shares across multiple transactions.
NASDAQ
Rapport Therapeutics, Inc. executive Yeleswaram Krishnaswamy reports a transaction involving common stock under a pre-arranged trading plan.
NASDAQ
Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, sold 10,000 shares of common stock for approximately $280,000 through a pre-arranged trading plan.
NASDAQ
Rapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, sold 10,115 shares of common stock for approximately $30 per share under a pre-arranged 10b5-1 trading plan.
NASDAQ
Rapport Therapeutics CEO Abraham Ceesay executed pre-planned sales of over 10,000 shares of common stock totaling approximately $320,000 through Rule 10b5-1 trading plans.
NASDAQ
Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock and exercised options for 6,000 shares under a pre-arranged trading plan.
NASDAQ
Rapport Therapeutics' Chief Medical Officer, Jeffrey Sevigny, was granted 130,000 stock options with an exercise price of $27.75, vesting over four years.
NASDAQ
Rapport Therapeutics, Inc. CEO Abraham Ceesay reported the acquisition of 428,000 stock options with an exercise price of $27.75.
NASDAQ
Rapport Therapeutics' Chief Financial Officer, Troy A. Ignelzi, was granted 148,000 stock options with an exercise price of $27.75.
NASDAQ
Rapport Therapeutics' Chief Development Officer, Krishnaswamy Yeleswaram, was granted 120,000 stock options with an exercise price of $27.75.
NASDAQ
Rapport Therapeutics' Chief Scientific Officer, David Bredt, was granted 103,000 stock options with an exercise price of $27.75.
NASDAQ
Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, was granted 132,000 stock options with an exercise price of $27.75.
NASDAQ
Rapport Therapeutics CEO Abraham Ceesay sold a total of 10,916 shares of common stock through pre-arranged trading plans.
NASDAQ
Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock on January 15, 2026, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Rapport Therapeutics' Chief Scientific Officer, David Bredt, reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.
NASDAQ
Rapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, reported the vesting of 9,000 performance-based restricted stock units and the subsequent sale of 2,840 shares to cover tax obligations.
NASDAQ
Rapport Therapeutics CEO Abraham Ceesay executed sales of company common stock totaling approximately $323,588 through pre-arranged 10b5-1 trading plans.
NASDAQ
Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold a total of 8,500 shares of common stock on December 15, 2025, through a pre-arranged 10b5-1 trading plan.
NASDAQ
Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, exercised stock options and immediately sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
Rapport Therapeutics CEO Abraham Ceesay disclosed modest open-market sales executed under a pre-set Rule 10b5-1 plan, while retaining a substantial stake.
NASDAQ
Rapport Therapeutics’ Chief Scientific Officer David Bredt sold 8,500 shares on November 17, 2025 under a pre-set Rule 10b5-1 trading plan, retaining 401,142 shares.
NASDAQ
Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Rapport Therapeutics CEO Abraham Ceesay sold 10,916 shares of common stock for approximately $281,930 through pre-arranged 10b5-1 trading plans.
NASDAQ
Rapport Therapeutics, Inc. CEO Abraham Ceesay reported the sale of 76,420 shares of common stock for approximately $2.01 million through pre-arranged 10b5-1 trading plans.
NASDAQ
Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock through a pre-arranged 10b5-1 trading plan.
NASDAQ
Rapport Therapeutics Director Reid M. Huber purchased 20,400 shares, indicating insider confidence.
NASDAQ
Rapport Therapeutics Director Steven M. Paul increased his indirect beneficial ownership by acquiring 41,666 shares of common stock through Paul Capital Strategy III Fund LLC.